Synthesis of C-4-modified Zanamivir Analogs As Neuraminidase Inhibitors and Their Anti-Aiv Activities

Deju Ye,Woo-Jin Shin,Ning Li,Wei Tang,Enguang Feng,Jian Li,Pei-Lan He,Jian-Ping Zuo,Hanjo Kim,Ky-Youb Nam,Weiliang Zhu,Baik-Lin Seong,Kyoung Tai No,Hualiang Jiang,Hong Liu
DOI: https://doi.org/10.1016/j.ejmech.2012.06.033
IF: 7.088
2012-01-01
European Journal of Medicinal Chemistry
Abstract:With the introduction of bioisosteres of the guanidinium group together with scaffold hopping, 35 zanamivir analogs with C-4-modification were synthesized, and their inhibitory activities against both group-1 and group-2 neuraminidase (H5N1 and H3N2) were determined. Compound D26 exerts the most potency, with IC(50) values of 0.58 and 2.72 μM against N2 and N1, respectively. Further preliminary anti-avian influenza virus (AIV, H5N1) activities against infected MDCK cells were evaluated, and D5 exerts ∼58% protective against AIV infection, which was comparable to zanamivir (∼67%). In a rat pharmacokinetic study, compound D5 showed an increased plasma half-life (t(1/2)) compared to zanamivir following either intravenous or oral administration. This study may represent a new start point for the future development of improved anti-AIV agents.
What problem does this paper attempt to address?